Advaxis, Inc. (NASDAQ:ADXS), a clinical stage biotechnology company developing cancer immunotherapies, today announced its combination study of axalimogene filolisbac (AXAL) with AstraZeneca’s anti-PD-L1 durvalumab has completed the second dose-escalation cohort and has commenced enrollment for the Part A expansion and Part B phases of the study.

The study is evaluating the safety and efficacy of combination treatment with AXAL and durvalumab in patients with advanced, recurrent or refractory human papillomavirus (HPV)-associated cervical cancer and HPV-associated head and neck cancer.

The goal of the Part A expansion is to enroll 20 patients with HPV-associated head and neck cancer to receive AXAL at 1×109 cfu plus 10 mg/kg of durvalumab. Part B of the trial will evaluate AXAL at 1×109 cfu with 10mg/kg of durvalumab in patients with cervical cancer, with the goal to randomize 45 patients to a durvalumab monotherapy and 45 patients for the combination therapy. (Original Source)

Shares of Advaxis are currently trading at $7.84, down $0.06 or -0.76%. ADXS has a 1-year high of $22.20 and a 1-year low of $5.21. The stock’s 50-day moving average is $8.27 and its 200-day moving average is $7.97.

On the ratings front, Advaxis has been the subject of a number of recent research reports. In a report issued on July 15, Jefferies analyst Brian Abrahams assigned a Buy rating on ADXS. Separately, on July 6, FBR’s Vernon Bernardino reiterated a Buy rating on the stock .

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Brian Abrahams and Vernon Bernardino have a total average return of 5.8% and -21.6% respectively. Abrahams has a success rate of 61.1% and is ranked #536 out of 4079 analysts, while Bernardino has a success rate of 26% and is ranked #3990.

Advaxis, Inc. is a clinical-stage biotechnology company, which intends to develop immunotherapies for cancer and infectious diseases. The company’s platform technology is designed to generate a comprehensive immune response by serving as its own adjuvant, directing antigen presentation, increasing tumor infiltrating killer T-cells, and decreasing Tregs/MDSCs in the tumor.